UCB (EBR:UCB) UCB Media Room: Acquisition and disposal of own shares

Directive transparence : information réglementée

08/07/2022 20:01
https://mb.cision.com/Public/18595/3599167/933dfd34d760174d_800x800ar.png ** Acquisition and disposal of own shares ------------------------------------------------------------ Brussels (Belgium), 8 July 2022 =E2=80=93 20:00 (CEST) =E2=80=93 Regulated = information=C2=A0 Acquisition of own shares In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi= ng the Belgian Code on Companies and Associations, UCB SA/NV (=E2=80=9CUCB= =E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby disclose= s certain information in relation to its Share Repurchase Program 2022.=C2= =A0 Under this program, UCB has requested a financial intermediary to repurchas= e up to 500 000 UCB shares on its behalf under the terms of a discretionary= mandate agreement with initial validity until 31 August 2022, effective as= from 28 June 2022, to cover current and future obligations under UCB's Lon= g Term Incentive Plans for its personnel. In the framework of this Share Repurchase Program 2022, UCB repurchased 145= .276 UCB shares on Euronext Brussels in the period from 1 July 2022 up to a= nd including 7 July 2022, as follows:=C2=A0 https://mb.cision.com/Public/18595/3599167/b2b3d83d53a6b000_800x800ar.png For consistency reasons, UCB confirms that during the same period, it has n= ot disposed of any UCB shares within the framework of the Long-Term Incenti= ve Program of the UCB Group. This press release is available on UCB SA/NV=E2=80=99s website via the foll= owing link (https://www.ucb.com/stories-media/Press-Releases) . For further information, contact UCB:=C2=A0 Investor Relations Antje Witte=C2=A0 T +32 2 559 94 14 antje.witte@ucb.com Corporate Communications Laurent Schots=C2=A0 T+32 2 559 92 64 laurent.schots@ucb.com =C2=A0=C2=A0 =C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With approximately 8 600 peopl= e in nearly 40 countries, the company generated revenue of =E2=82=AC 5.8 bi= llion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us = on Twitter: @UCB_news =C2=A0 GenericFile 220708 - Acquisition and disposal of own shares ENG final (https://mb.cisio= n.com/Public/18595/3599167/adb92fa6713d24dc.pdf) GenericFile 220708 - Verwerving en vervreemding van eigen aandelen NL final (https://mb= .cision.com/Public/18595/3599167/b1ac9e3a83b13024.pdf) GenericFile 220708 - Acquisition and disposal of own shares ENG final (https://mb.cisio= n.com/Public/18595/3599167/b471203cbfddb7b4.pdf) Image Chart 1 July 8 2022 (https://mb.cision.com/Public/18595/3599167/b2b3d83d53a= 6b000_org.png) ______________________ If you would rather not receive future communications from UCB SA, please g= o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x110669x1x6868579x2400= 0x6&Email=3Dregnews%40symexglobal.com. UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium